Incyte Corporation (BIT:1INCY)

Market Cap	13.65B
Revenue (ttm)	3.90B
Net Income (ttm)	741.55M
Shares Out	n/a
EPS (ttm)	3.72
PE Ratio	18.41
Forward PE	13.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	0
Open	66.10
Previous Close	66.10
Day's Range	66.10 - 66.10
52-Week Range	47.33 - 79.44
Beta	n/a
RSI	99.42
Earnings Date	Jul 29, 2025

About Ligand Pharmaceuticals

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.